Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Blood (2024) 144 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2024-204021

Published: 2024

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2023-189193

Published: 2023

Journal Articles

Decoding the Historical TALE: COVID-19 Impact on Hematological Malignancy Patients - Insights from 2020 to 2022

Francesco Marchesi, Jon Salmanton-García, Francesca Farina, Barbora Weinbergerova, Federico Itri, Julio Dávila-Valls, Sonia Martín-Pérez, Andreas Glenthoej, Ditte Hersby, Maria Gomes Da Silva, Raquel Nunes-Rodrigues, Raul Cordoba, Alberto Lopez Garcia, Ziad Emarah, Shaimaa El-Ashwah, Yavuz M. Bilgin, Laman Rahimli, Oliver Cornely, Livio Pagano

Blood (2023) 142 (Supplement 1): 1067.

https://doi.org/10.1182/blood-2023-188942

Published: 2023

Journal Articles

Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes

Blood (2023) 142 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2023-189358

Published: 2023

Journal Articles

Genetic Engineering of Hematopoietic Progenitor Stem Cells for Targeted IFN-α Immunotherapy Reprogramming the Solid Tumor Microenvironment: A First-in-Man Study in Glioblastoma Multiforme (NCT03866109)

Blood (2023) 142 (Supplement 1): 4850.

https://doi.org/10.1182/blood-2023-178212

Published: 2023

Journal Articles

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap van Doesum, Yavuz M. Bilgin, Alberto López-García, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerová, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valković, Iker Falces-Romero, Sonia Martín-Pérez, Moraima Jiménez, Julio Dávila-Valls, Martin Schönlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, László Imre Pinczés, Caterina Buquicchio, Klára Piukovics, Irati Ormazabal-Vélez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Méndez, José-Ángel Hernández-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciumè, Cristina de Ramón, Nick de Jonge, Josip Batinić, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemí Fernández, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdeněk Ráčil, Marcio Nucci, Miloš Mladenović, Raphaël Liévin, Michaela Hanáková, Stefanie Gräfe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adžić-Vukičević, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely

Blood (2022) 140 (26): 2773–2787.

https://doi.org/10.1182/blood.2022017257

Published: 2022

Includes: Supplemental data

Journal Articles

Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Blood (2022) 140 (Supplement 1): 4575–4576.

https://doi.org/10.1182/blood-2022-165975

Published: 2022

Journal Articles

Patients Reported Outcomes (PROs) Are Still Unsatisfactory Among AML Long-Term Survivors: The Impact of Chronic GvHD in a Prospective Study on 15 Years Transplant Activity

Maria Teresa Lupo-Stanghellini, Camilla Riva, Alessandro Bruno, Simona Piemontese, Raffaella Greco, Sarah Marktel, Sara Mastaglio, Elisabetta Xue, Daniela Clerici, Francesca Farina, Fabio Giglio, Elisa Diral, Luca Vago, Consuelo Corti, Andrea A. Assanelli, Massimo Bernardi, Jacopo Peccatori, Matteo Giovanni Carrabba, Fabio Ciceri

Blood (2022) 140 (Supplement 1): 10571–10572.

https://doi.org/10.1182/blood-2022-169554

Published: 2022

Journal Articles

TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN-α within Glioblastoma Tumor Microenvironment

Blood (2021) 138 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2021-150230

Published: 2021

Journal Articles

Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Blood (2021) 138 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2021-146908

Published: 2021

Journal Articles

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

Chiara Cattaneo, Francesco Marchesi, Valentina Bonuomo, Nicola S Fracchiolla, Anna Candoni, Marianna Criscuolo, Lucia Prezioso, Crescenza Pasciolla, Maria Ilaria Del Principe, Michelina Dargenio, Giuseppe Tarantini, Maria Enza Mitra, Francesca Farina, Federica Colnaghi, Mariarita Sciumè, Gianpaolo Nadali, Alessandro Busca, Giuseppe Rossi, Livio Pagano

Blood (2021) 138 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2021-149080

Published: 2021

Journal Articles

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Bernhard Gentner, MD, Francesca Farina, MD, Matteo Giovanni Carrabba, MD, Magda Marcatti, MD, Stefania Girlanda, MD, Gabriele Antonarelli, MD, Capotondo Alessia, PhD, Stefania Mazzoleni, PhD, Carlo Russo, MD, Luigi Naldini, MD PhD, Fabio Ciceri, MD

Blood (2019) 134 (Supplement_1): 2064.

https://doi.org/10.1182/blood-2019-123749

Published: 2019

Journal Articles

Infections in Patients with Lymphoproliferative Diseases Treated with Target Therapy. Italian Multicentric Retrospective Study Seifem 2017

Gianpaolo Nadali, MD, Gessica Marchesini, MD, Davide Facchinelli, MD, Francesca Farina, MD, Maria Chiara Tisi, MD, Federica Lessi, MD, Francesco Marchesi, Chiara Cattaneo, MD, Anna Candoni, MD, Rosa Fanci, Lucia Prezioso, MD, Luisa Verga, MD, Luca Laurenti, MD, Fabio Trastulli, MD, Marco Picardi, MD, Maria Ilaria Del Principe, MD, Ronaldo Silva, PhD, Alessandro Busca

Blood (2018) 132 (Supplement 1): 4164.

https://doi.org/10.1182/blood-2018-99-111518

Published: 2018

Journal Articles

Immune Reconstitution Is a Predictive Biomarker of Chronic Graft-Versus-Host Disease: Analysis of 307 Consecutive Patients

Blood (2018) 132 (Supplement 1): 4579.

https://doi.org/10.1182/blood-2018-99-113855

Published: 2018

Journal Articles

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Blood (2018) 132 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2018-99-117293

Published: 2018

Journal Articles

ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia

Antonio Niro, Rocco Piazza, MDPhD, Gabriele Merati, Alessandra Pirola, MSc, Carla Donadoni, MSc, PhD, Diletta Fontana, MSc, Sara Redaelli, PhD, Caterina Mezzatesta, Rossella Renso, MD, Francesca Farina, MD, Delphine Rea, Carlo Gambacorti-Passerini, MD

Blood (2015) 126 (23): 3652.

https://doi.org/10.1182/blood.V126.23.3652.3652

Published: 2015

Journal Articles

A Pathologic Abdominal Ultrasonography At Diagnosis Of CLL Significantly Reduces The Time To Progression In Patients With Rai 0 Or Rai 1 Disease

Fausto Rossini, MD, Caterina Cecchetti, Francesca Farina, Marianna Sassone, Chiara Scollo, Sara Pezzatti, Silvia Bolis, Angelo Belotti, Sofia Bozzani, Alessandra Perego, Enrico Maria Pogliani, MD

Blood (2013) 122 (21): 2869.

https://doi.org/10.1182/blood.V122.21.2869.2869

Published: 2013

Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood (2013) 122 (21): 368.

https://doi.org/10.1182/blood.V122.21.368.368

Published: 2013

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Decoding the Historical TALE: COVID-19 Impact on Hematological Malignancy Patients - Insights from 2020 to 2022

Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes

Genetic Engineering of Hematopoietic Progenitor Stem Cells for Targeted IFN-α Immunotherapy Reprogramming the Solid Tumor Microenvironment: A First-in-Man Study in Glioblastoma Multiforme (NCT03866109)

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Patients Reported Outcomes (PROs) Are Still Unsatisfactory Among AML Long-Term Survivors: The Impact of Chronic GvHD in a Prospective Study on 15 Years Transplant Activity

TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN-α within Glioblastoma Tumor Microenvironment

Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Infections in Patients with Lymphoproliferative Diseases Treated with Target Therapy. Italian Multicentric Retrospective Study Seifem 2017

Immune Reconstitution Is a Predictive Biomarker of Chronic Graft-Versus-Host Disease: Analysis of 307 Consecutive Patients

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia

A Pathologic Abdominal Ultrasonography At Diagnosis Of CLL Significantly Reduces The Time To Progression In Patients With Rai 0 Or Rai 1 Disease

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only